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 Prostate cancer is the abnormal growth and proliferation of previously normal cells of the 
prostate and has the second highest incidence in men worldwide.  Physiologic manipulation of 
AMP-activated protein kinase (AMPK), a highly conserved enzyme responsible for regulation of 
energy homeostasis during metabolic stress, is a potential treatment, especially for metastatic, 
castration-resistant prostate cancers.  AMPK is a known inhibitor of the enzyme mTOR, the final 
enzyme in the PKT/AKT/mTOR pathway responsible for cell growth and proliferation signaling.  
The hypothesis of this project is that activation of AMPK leads to increased mTOR-dependent 
mitophagy and subsequent autophagy in prostate cancer cells.  The overall aim of this project is 
to establish a role between activated AMPK and mTOR dependent mitophagy and autophagy.  
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A Brief Introduction to Cancer 
Cancer can be defined as the development of abnormal growth and division in derivations 
of normal cells, leading to cancerous stem cells (CSCs).  CSCs are believed to interrupt body-
preserving homeostasis (1). Although there are differing theories regarding the origin of cancer 
cells (1-3), it is widely agreed upon that all cancer cells are similar in that they share a group of 
characteristics and together these characteristics encourage abnormal growth, proliferation, and 
migration.  For clarification, this project will define growth as in increase in individual cell size, 
proliferation as an increase in individual numbers of cells within a population via division or other 
such reproduction, and migration as the movement of those cells throughout their host 
organism.  One review suggests the cardinal characteristics defining cancer cells are the 
developed abilities to sustain proliferative signaling, evade growth suppressors, activate invasion 
and metastasis, enable replicative immortality, induce angiogenesis, and resist cell death (4).  
These may be influenced by a phenomenon known as Warburg’s Effect, a drastic change in 
physiology seen in cancer cells, which aids in their rapid proliferation and migration (5). 
Again, opinions differ regarding cancer cell etiology.  The stem cell division theory of 
cancer, a review published in 2018, theorizes risk of cancer cell development is correlated with 
the number of divisions the cell has undergone since its original ancestor, the zygote.  This theory, 
the stem cell division theory, suggests that cancer-associated DNA mutations are only a class of 
cancer-promoting factors.  This review suggests other classes of cancer-promoting factors include 





A year later, Niculescu published a review discussing the atavistic and stochastic cancer 
cell theories.  Niculescu’s review favored the atavistic theory, which suggests genetic and 
epigenetic influences, including post-translational modification, non-specifically transform cells, 
thus activating biochemical mechanisms and population dynamics conserved from the cells’ 
primitive, unicellular ancestors.  The stochastic theory suggests cancer occurs in otherwise 
normal cells due to accumulation of DNA mutations (2).  As an interesting side note, the 
stochastic theory is named after the differential equation it is based upon, which is 
mathematically analytical in nature and beyond the scope of this project (7).  Argument in favor 
of the atavistic theory includes evidence suggesting that loss of gene expression, the most clearly 
understood epigenetic influence on cancer cell development, occurs via transcription silencing 
ten times more often than it occurs via genetic mutations (8). 
Yet another research group studying cancer cell origin suggests that for cancer cells to 
migrate, or become metastatic, the cancerous cell population as a whole must have 
heterogeneity and stochasticity.  These researchers believe individual cells in the population have 
specific migration capacities and individual cell migration capacities change temporally 
throughout each cell’s existence.  Furthermore, these researchers suggest heterogeneity is 
inherent in a metastatic cancer cell population, leading to unique challenges when developing a 
model for metastasis (3). 
Although the origin of cancer cells is debatable, the following review of cancer 





repair, and cell reproduction.  This investigation will be focused on normal physiologic processes 
and the deviations from these pathways related to cancer development and progression. 
The cell cycle can be described in layman’s terms as the process by which cells of the 
body, or any eukaryotic cells for that matter, carry out their daily function and divide (9-12).  For 
this study, discussion of the cell cycle will focus on human somatic cells, diploid cells of the body 
at risk of becoming malignant and from which models of cancer have been previously derived 
(13).  Somatic cell division as a normal means of proliferation, and thus tissue maintenance, is 
known as mitosis and will be discussed in brief. 
The cell cycle is mostly spent in interphase, a time during which cell growth and 
preparation for division occurs.  Cells spend approximately 90% of the cell cycle in interphase, 
which includes the phases G1, S, and G2; times when growth without DNA replication, DNA 
replication, and synthesis of proteins to prepare for division take place, respectively (10).  During 
the S phase, when DNA is replicated, each strand of DNA is unwound and copied via highly specific 
mechanisms to produce two identical copies of that strand.  While the DNA is being unwound, 
replicative machinery travels along each strand of original DNA, ultimately creating two semi-
conservative copies of the original DNA strand (14).  These two copies are known as sister 
chromatids, which are connected via a centromere in a cohesin complex to mark the beginning 
of mitosis (15). 
Mitosis is a brief phase of the cell cycle and begins during a vague period of time when 
chromosomal condensation can be observed under microscope.  Chromosomal condensation 





in preparation for mitosis, but remains reversible until the first subphase of mitosis, known as 
prophase.  There is a brief period at the end of G2 known as antephase, during which time the 
cell has not yet completely committed to mitosis.  Cell commitment to mitosis usually occurs well 
into prophase and is physiologically indicated by the accumulation of cyclin dependent kinase 1 
and cyclin B complexes in the nucleus and nuclear envelope breakdown (NEB) (16). 
The transition from terminal G2 antephase and commitment to mitosis in late prophase 
switch is regulated by at least two checkpoints.  One checkpoint prevents entry into mitosis in 
response to DNA breaks and the other checkpoint responds to a variety of acute stress factors, 
ranging from drug treatments to light exposure during microscopy observation.  Although 
different mechanisms are used to do so, both checkpoints prevent mitotic entry by decreasing 
activity of cyclin B and A dependent kinases.  Once committed, the cell must continue through 
mitosis until the cell is split into two daughter cells in a process known as cytokinesis.  Otherwise, 
the cell may face apoptosis (16). 
Complete condensation of chromosomes, centrosome migration, and completion of NEB 
characterize the first official phase of mitosis, known as prophase (17).  Centrosomes are 
complexes of proteins that migrate to opposite ends of the cell and are responsible for the 
organization of microtubules (18).  During prometaphase, microtubule arrays from centrosomes 
at both side of the cell specifically attach to cohesive proteins known as kinetochores on each 
semi-conservatively produced sister chromatid.  Specific bonding between microtubules and 
kinetochores ensures that each sister chromatid of a duplicated chromosome is allocated to a 





key in mitotic progression because this checkpoint prevents mitotic progression in cases of 
insufficient or inappropriate spindle-kinetochore complexing.  The spindle assembly checkpoint 
ensures each daughter cell receives only one sister chromatid from each duplicated chromosome 
and that this process occurs in a timely manner (19). 
During metaphase, condensed chromosomes align centrally within the cell and cohesive 
proteins between chromatids dissolve, allowing for the separation of sister chromatids during 
anaphase (17).  Telophase occurs once each pair sister chromatids have reached opposing poles 
of the cell.  Telophase involves the development of nuclear envelopes and the decondensation 
of chromosomes.  Soon after, the cell separates equally into two daughter cells in a process 
known as cytokinesis.  The cell then enters G1 and remains particularly sensitive to the presence 
of nutrients and growth factors for approximately 3 hours, after which time the cell may re-enter 
the cell cycle if adequate nutrition and signaling is available (17).  Mitotic exit, a popular topic 
among cancer researchers, signals the completion of the cell cycle (16). 
Mitigation of DNA mutations is an important concept to understand when trying to 
understand cancer-associated deviations from normal cell physiology.  As discussed above, 
division of normal cells produces two genetically identical daughter cells; any change in the 
genetic makeup that occurs, whether due to an error in copying the DNA or from DNA-damaging 
factors, is a mutation.  Compared to their haploid germline counterparts, human somatic cells 
have 46 chromosomes in 23 pairs, with one chromosome from each pair derived from maternal 
genes and the other from paternal genes.  Mutations that alter the number of chromosomes 





of chromosomes and this condition can be described as aneuploidy (11).  Because of associated 
chromosomal instability, cancer cell genomes are diverse when compared to their non-cancerous 
counterparts.  Differences between tumors and heterogeneity between cells of tumors present 
rampant and greatly varying aneuploidy.  Aneuploidy can influence tumor development, therapy 
response, relapse, and many other aspects of cancer development and treatment (20).  
Checkpoints and DNA repair pathways are two ways the physiologically normal cell decreases the 
occurrence of and repairs random mistakes made throughout the cell cycle. 
(i) Checkpoints throughout the cell cycle represent one major means of DNA mutation 
mitigation (11).  Each cell cycle checkpoint consists of a sensor to recognize the 
problem or mistake, a signal produced by the sensor and propagated by means of 
signal transduction pathways or other signaling mechanisms, and a response element 
of cell cycle machinery, targeted to lock cell cycle progression (21).  One checkpoint 
previously discussed in this manuscript is the spindle assembly checkpoint, which 
mitigates aneuploidy during mitosis.   
Two major checkpoints of the cell cycle related to DNA replication include one between 
G1 and S and another between G2 and mitosis (11, 16).  DNA replication checkpoints are most 
directly regulated by two main proteins: cyclin-dependent kinases (CDKs) and cyclins.  When 
bound to form CDK-cyclin complexes, these proteins function to inhibit processes preventing 
DNA replication and encourage the synthesis of proteins made for mitosis (10). 
An important note is that CDKs, kinases present to phosphorylate other compounds, 





cyclins and cyclins are only produced at certain times in the cell cycle (11).  Stringent control 
of cyclin protein and cyclin dependent kinase binding regulates progression of the cell cycle 
and deregulation of these processes is correlated with cancer development (22).  During G1, 
cyclins D and E are produced and bind to CDK4 and CDK2, respectively.  The CDK4-CyclinD 
complex phosphorylates and inactivates a protein known as retinoblastoma (Rb), which is a 
tumor suppressor protein normally responsible for inhibition of DNA replication.  During the 
S phase, cyclin A is produced and binds with CDK 2 to activate DNA replication.  In the G2 
phase, cyclin B is produced and binds with CDK1 to activate mitosis.  Though these pairings 
of CDK – cyclin complexes may seem nonsensical, a key point in understanding the role of 
cell-cycle checkpoints is that precise synthesis of cyclin at specific times throughout the cell’s 
cycle is imperative for normal cell growth and proliferation (11). 
(ii) DNA repair pathways are another means by which the cell naturally prevents 
excessive DNA damage and subsequent mutation.  There are various sub-categories 
of internal (endogenous) and external (exogenous) sources of DNA damage, with 
endogenous DNA damage pathways being an aberrant by-product of natural and 
necessary DNA replication (23). 
Sources of endogenous DNA damage include DNA replication errors, base mismatches, 
topoisomerase-DNA complexes, spontaneous base deamination, development of abasic 
sites, oxidative DNA damage, and DNA methylation, all of which may warrant a review in and 
of themselves, though this is beyond the scope of this project (23).  Though a variety of factors 





approximately 10-10 mutations per base pair per generation in eukaryotic cells (24).  Aberrant 
geometrical structure of abnormally paired DNA initiates DNA damage response (DDR), the 
process by which DNA damage is identified and flagged for target by repair mechanisms (23). 
In some circumstances, such as alkylation of DNA, damage can be reversed.  Knockout of 
enzymes responsible for reversal of alkylation of DNA is associated with various metabolic 
diseases and cancers (23).  Base excision repair (BER) is the pathway through which small 
forms of DNA damage can be repaired.  For larger errors, the cell employs nucleotide excision 
repair (NER), mismatch repair (MMR), interstrand cross-link repair (ICL), and/or translesion 
synthesis (23).  Single strand breaks (SSBs), which may be correlated with oxidative damage, 
abasic sites, and/or activity of DNA topoisomerase 1 (TOP1), require cell engagement in single 
strand break repair (SSBR); each source of damage having a unique respective SSBR pathway 
(23). 
The Warburg Effect is a phenomenon seen in proliferating and developing cells, including 
those of tumors, with normally functioning mitochondria and in the presence of adequate 
quantities of oxygen.  Cells experiencing the Warburg Effect alter their metabolism to 
dramatically increase glucose uptake and fermentation of glucose to lactate (25).  Fermentation 
of glucose to lactate occurs via a process known as aerobic glycolysis (26), a term which has been 
used synonymously with the Warburg Effect (27).  Though this dramatic change in metabolism 
was discovered and coined in the mid-1920s, the mechanisms, onset, and impact of the effect 





Cells exhibiting the Warburg Effect deviate from normal cell metabolism when pyruvate, the 
final product of glycolysis, accumulates in the cytosol due to increased glucose uptake by the cell 
and decreased flux of pyruvate into the mitochondria (25, 29).  This and similar examples of 
imbalanced metabolic supply and demand have been termed overflow metabolism, a metabolic 
shift that creates substrates for anabolic metabolism in times of limited nutrition (30).  For this 
discussion, overflow metabolism and the Warburg Effect will be distinguished by the observation 
of overflow metabolism in cancer cells, specifically, during the Warburg Effect.  Increased glucose 
uptake is facilitated via expression of different membrane glucose transporter isoforms, including 
increased expression of high-affinity GLUT-1 and GLUT-3 (29, 31).  Disregarding glycolysis, 
pyruvate can also be produced in the cytosol via oxidation of lactate by lactate dehydrogenase, 
reformation of pyruvate from malate via cytosolic malic enzyme, and catabolism of amino acids, 
primarily via alanine transaminase (32). 
An important note is that many cancer cells express a splice variant isoform of pyruvate 
kinase, the final and pyruvate-producing enzyme involved in glycolysis.  The isoform often seen 
in cancer cells is pyruvate kinase M2, a fetal isoform of the enzyme.  Pyruvate kinase M2 has an 
increased quantity of tyrosine residues.  In rapidly growing cells, which are known to exhibit 
increased activation of tyrosine kinase signaling, the additional tyrosine residues of pyruvate 
kinase M2 are phosphorylated.  Phosphorylated tyrosine residues inhibit stimulation of pyruvate 
kinase M2 by fructose 1,6-bisphosphate.  This results in a slowing of glycolysis and an 





Normally, pyruvate in the cytosol is transported into the mitochondria via a membrane 
transport system that shuttles pyruvate across the inner mitochondrial membrane (32).  Once 
inside the mitochondria, pyruvate is normally converted to acetyl-coenzyme A (acetyl-coA) via 
pyruvate dehydrogenase (PDH) (34).  During times of nutrient deprivation, cells have also been 
observed converting pyruvate to acetate via keto acid dehydrogenases within the mitochondria 
and converting acetate to acetyl-coA via enzymes within a family of acetyl-coA synthetases in the 
cytosol (34).  Acetyl-coA is fed into the tricarboxylic acid (TCA) cycle, which breaks acetyl-coA 
down via oxidative phosphorylation by the enzyme acetyl-coA carboxylase (ACC), an enzyme 
responsible in part for lipid metabolism (31).  In humans, the isoform ACC1 produces malonyl-
coA for lipid metabolism in lipogenic tissues and the isoform ACC2 regulates beta-oxidation of 
fatty acids (35).  Because these ACC enzymes are so heavily involved in lipid metabolism, they 
have become a target for potential treatments of metabolic disease (35) and cancer (36). 
The TCA cycle produces the energy-containing molecule guanosine triphosphate (GTP) and 
reduces nicotinamide adenine dinucleotide (NAD+) and flavin adenine dinucleotide (FAD2+) to 
produce the electron-carrying molecules NADH and FADH2, respectively (31).  Electrons carried 
by NADH and FADH2 are carried to the respiratory chain located within the inner membrane of 
mitochondria, where electrons are shuttled along a chain of enzymes to produce a proton 
gradient within the intra-membrane space of the mitochondrion.  Due to the gradient, protons 
from the intra-membrane space flood into the inner mitochondrial space through an enzyme 
complex known as adenosine triphosphate synthase (ATP synthase), which produces adenosine 





Effect display deregulation of genes of the TCA cycle, including upregulation of glucose 
transporters, lactate dehydrogenase A, fatty acid transporters, fatty acid synthase, f A 
carboxylase (ACC), adenosine triphosphate citrate lyase, citrate synthase, sodium-coupled amino 
acid transporters, glutaminase, dihydrolipoamide S-succinyltransferase, and alpha-ketoglutarate 
dehydrogenase complex and downregulation of OGDH (31).  Mutations in isocitrate 
dehydrogenases 2 and 3, succinate dehydrogenase, and fumarase are seen in cancer as well (31).  
Researchers have identified deregulation and mutation in genes involved in components of the 
mitochondrial respiratory chain as well (37). 
 ATP is produced in the mitochondria via oxidative phosphorylation to fuel viability, growth, 
and proliferation of cells (37).  In normal human somatic cells, oxidative phosphorylation through 
the TCA cycle and respiratory chain of the mitochondria is the most efficient means of ATP 
production from glucose in the presence of functioning mitochondria and adequate oxygen (27, 
38, 39).  Though the Warburg Effect is shown to dissociate glucose influx, pyruvate production, 
and the TCA cycle (40), the Warburg Effect is shown to benefit cancer cells via increase in the rate 
of ATP synthesis  (27, 38), increased biosynthesis (25, 30, 34, 41-43), enhanced tumor 
microenvironment (25, 29, 30, 34, 42-44), and sustained cell signaling (25, 29, 43, 45, 46). 
 Cancer, though hard to define, is an accumulation of aberrations in normal cell physiology 
that results in rapid growth, proliferation, and possibly metastasis in previously normal cells.  
Though the origin of cancer cells can be argued, it is clear that a variety of mutations present 
themselves in cancer cells, including mutations of genes responsible for cell cycle checkpoints, 





repair pathways to mitigate and resolve issue related to deregulation or mutation of these genes, 
these errors are still correlated to cancer development.  Additionally, cancer cells exhibit a form 
of overflow metabolism known as the Warburg Effect, which increases glucose uptake and 
aerobic glycolysis to provide energy and building components of the cell. 
Prostate Cancer 
Prostate development is marked in the embryo by the interaction of wolffian ducts, 
müllerian ducts, the urogenital sinus, and the fetal gonads (47).  Sexual differentiation in male 
embryos is a two-part process beginning with development of the male gonads, or testis, from 
the urogenital ridge.  Development of the testis is marked by sufficient differentiation of bi-
potential pre-Sertoli cells to Sertoli cells (47-49).  The Sex-determining Region Y gene, which is 
expressed by pre-Sertoli cells, is found on the Y chromosome, which is donated to the zygote by 
the paternal spermatozoan (47, 50).  Expression of Sex-determining Region Y creates a positive 
feedback loop between Sox9, an enzyme involved in production of anti-müllerian hormone by 
Sertoli cells, and Fgf9, an enzyme responsible for repression of the ovarian gene Wnt4 (49).   
In humans, development of the wolffian duct begins between 25 to 30 days after 
conception and the wolffian ducts initially aid the mesonephros in the secretion of toxins that 
will eventually be secreted by the fully developed kidney, also known as the metanephros (47, 
51, 52).  At approximately 43 days after conception, the wolffian duct elongates to link the 
hindgut, which caudally becomes the cloaca, to the mesonephros and gonads (47, 53).  The cloaca 
is a temporarily present structure in the developing embryo between embryological weeks 4 and 





(54).  Between embryological days 46 and 48, the urorectal septum forms, dividing the cloaca 
into the urogenital sinus and hindgut (47, 53, 54).  Prostatic ducts, eventually forming the adult 
prostate, originate from the urogenital sinus (47).  Müllerian ducts begin development by 
elongating parallel to the wolffian ducts at approximately 6 weeks gestation.  By the eighth week 
of gestation, the müllerian duct runs parallel, but between, the wolffian ducts.  At approximately 
the same time, the müllerian duct reaches the urogenital sinus, forming the müllerian tubercle.  
The müllerian tubercle forms the penile urethra in males (47).  This process is the first part of 
sexual differentiation in male embryos involves the degradation of the müllerian duct system and 
reinforcement, via androgens, of the wolffian duct system (47, 49). 
The second part of sexual differentiation in male embryos begins when Leydig cells are 
stimulated to produce the androgen hormone testosterone and includes masculinization of the 
urogenital sinus and external male genitalia, including development of the prostate.  In the 
human fetus, the prostate begins to bud from the urogenital sinus at approximately 10 weeks 
fetal age (47). 
 The prostate is a walnut-sized gland found at the base of the urinary bladder in adult male 
humans (47).  The prostate is located within the visceral layer of the pelvic fascia, which is a 
connective tissue separating the membranous peritoneum from the muscular pelvic walls and 
floor.  The peritoneum lines the abdominal cavity and extends into the pelvic cavity.  The right 
and left coxal/pelvic/hip bones and sacrum bone create the pelvic girdle, which provides skeletal 
framework for the greater and lesser pelves.  The lesser pelvis is surrounded by the inferior pelvic 





openings of the pelvic girdle, respectively.  The lesser pelvis surrounds the pelvic cavity and 
perineum, the two of which are separated by the muscles of the pelvic diaphragm.  The prostate 
is located within the pelvic cavity, which is continuous with the abdominal cavity, and receives 
blood supply primarily by prostatic branches of the inferior vesical arteries of the internal iliac 
artery.  From an anterior view, the prostate can be located between the internal urethral orifice 
of the bladder and the external urethral sphincter, surrounding a portion of the urethra 
commonly referred to as the prostatic urethra.  The base of the prostate closely relates to the 
neck of the bladder, the apex is in contact with the connective tissue superior to the urethral 
sphincter, and the posterior surface is related to the rectum (55). 
The prostate can be divided into three histologically and anatomically unique areas; the 
prostate-surrounding nonglandular fibromuscular stroma, the glandular peripheral zone, and the 
glandular central zone.  The wedge-shaped central zone creates the base of the prostate and 
surrounds the ejaculatory canal.  The peripheral zone forms the remainder of the prostate and 
surrounds a portion of the urethra distal to the prostate (47).  There is also a small, glandular 
region surrounding the prostatic urethra, which is known as the transition zone (47).   
Additionally, the prostate can be divided into three distinct lobes.  The isthmus, or 
anterior lobe, of the prostate lies anterior to the urethra and contains little glandular tissue.  The 
isthmus separates the right and left lobes of the prostate, which can be subdivided into 4 lobules 
based on proximity to the urethra and ejaculatory ducts: the inferoposterior, inferolateral, 
superomedial, and anteromedial lobules.  The four lobules of the right and left lobes of the 





The glandular regions and zones of the prostate are characterized by epithelial acini, or 
grape-shaped, glands (56).  Epithelial tissue is a type of connective tissue that lines many internal 
organs of the human body and plays a role in absorption of nutrients, secretion of hormones and 
enzymes, and forming a protective barrier in these areas (57).  The epithelial tissues of the 
prostate organize into a basal layer containing four cell types: secretory luminal, basal, 
neuroendocrine, and transit-amplifying (56, 58).   When damaged or under the stress of DNA 
mutation accumulation, epithelial cells activate intrinsic homeostatic mechanisms to replenish 
epithelial tissue.  For these reasons, it is crucial that epithelial cells have a degree of flexibility 
allowing for significant alterations of homeostatic mechanisms within each individual cell to 
sustain this vital tissue (57).  However, this epithelial plasticity has been implicated in cancer 
development (56, 57, 59). 
The mature and active prostate is considered essential to male fertility and health and is 
responsible for secretion of glycoproteins, trace elements, and metabolites citrate and spermine 
that encourage normal spermatozoa function and transport (47).  Semen, the ejaculate secreted 
by men during copulation, is approximately 2-5% spermatozoa and 95-98% fluids secreted by 
seminal vesicles, prostate epithelium, and bulbourethral glands, collectively known as the male 
accessory glands (50).  The prostate is arguably the most vital male accessory gland with regard 
to male fertility, owing to its pivotal role in activating pathways leading to ejactulation and 
subsequent sperm and capacitation (50).  One secretory product released by the prostate is 





Prostatitis, benign prostatic hyperplasia, and prostate cancer are the three major 
disease of the prostate (47, 50, 60-62).  Prostatitis (63) and benign prostate hyperplasia (47, 61, 
64, 65) are not cancerous, but prostatitis involves inflammation of the prostate and benign 
prostatic hyperplasia is non-cancerous growth (47, 50, 63, 65)  The transition zone of the prostate 
is the most common site of prostatitis and prostate carcinoma (47).  In conditions such as benign 
prostatic hyperplasia and cancerous prostate growth, prostate-specific antigen bypasses the 
blood-testis barrier and can be detected in the serum plasma of affected individuals (47, 60, 61, 
66).  However, it is important to note disagreement within the scientific and medical communities 
regarding the use of prostate-specific antigen screening for diagnosis of prostate pathology (67, 
68). 
Prostate cancer is described as abnormal and uncontrolled growth of previously normal 
cells of the prostate (69).  According to the American Cancer Society, prostate cancer is the 
second leading cause of death in men (69).  Postmortem studies conducted regardless of cause 
of death estimate 80% of men 80 years and older have histopathological evidence of prostate 
cancer, regardless of their diagnostic status (70).  Symptoms of prostate cancer include painful 
urination (dysuria), blood in the semen (hematuria), bone pain, and erectile dysfunction (ED) (66).  
Furthermore, estimates in the United Kingdom suggest the average patient may accrue nearly 
$70000 in additional healthcare costs yearly once diagnosed with cancer and a society may spend 
nearly $400,000 per million capita to adopt only one new chemotherapy agent (71).  Given this 





wellbeing of numerous patients and researchers are behooved to find a safe, efficient means of 
prostate cancer treatment. 
Common treatments (72) for localized prostate cancer include removal of the malignant 
tissue (radical prostatectomy) (73), chemotherapy (74), and radiotherapy (75).  Radical 
prostatectomy results in lower rates of overall prostate cancer mortality while chemotherapy 
and radiotherapy are more useful treatment for cases of metastatic, relapsing, or castration-
resistant prostate cancers (76). 
Though the origin of prostate cancer remains uncertain, there is evidence suggesting 
prostate cancer develops in correlation with an accumulation of mutations in rapidly dividing 
epithelial cells of the glandular prostate.  In most prostate cancers, the lumens of prostatic acini 
glands have lack of or disrupted basal membranes.  Additional evidence supports the theory that 
prostate cancer arises from basal cells of the prostate versus epithelial cells (56).  There is also 
growing evidence defining a relation between inflammation and the development of prostate 
cancer, which may play a role in the accumulation of DNA mutations (77). 
As implied above, prostate cancer has a variety of clinical presentations.  Some ways to 
describe prostate cancer are as primary, metastatic, relapsing, and/or castration-resistant, with 
the development of each unique prostate cancer influenced by the patient’s genomic and 
environmental factors (78-80).  Androgen deprivation therapy (ADT), which lowers testosterone 
levels, may be prescribed to a patient to physiologically treat the cancer.  Tumors that grow and 
proliferate despite ADT are described as castration-resistant (78).  Metastatic cells, cells able to 





especially malignant and are the primary cause of death from cancer (81).  Once a primary 
prostate cancer shows castration-resistance and continues to spread throughout the body, it can 
be classified as metastatic castration-resistant prostate cancer (mCRPC) (78).   
Genomic variability between prostate cancer genomes is believed to influence 
presentation and progression of the disease (65, 82-84).  Furthermore, genomic variability 
between prostate cancers may be driven by DNA mutations and malfunction of DNA repair 
pathways (83), mechanisms which have been discussed above.   
Integrative Clinical Genomics of Advanced Prostate Cancer, published in 2015, exhibits 
genomic analysis on 150 mCRPC biopsy samples previously treated with combination strategies 
involving inhibition of poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) by 
abiraterone acetate or enzalutamide and/or inhibition of aurora kinase (78).  Poly(adenosine 
diphosphate [ADP]–ribose) polymerase (PARP) is a family enzymes heavily involved in DNA repair 
that is responsible for detection of single-strand DNA breaks and orchestration of single strand 
break repair (85).  Aurora kinase inhibitors were used to treat cancer due to the overexpression 
of aurora kinase A in metastatic neuroendocrine prostate cancers.  Aurora kinase is a cell-cycle 
kinase that complexes to the transcriptional factor N-Myc, which is also overexpressed in some 
prostate cancers.  When complexed to aurora kinase A, N-Myc is stabilized, allowing the 
oncogene to suppress androgen receptor activity and encourage androgen-independent prostate 
cancer progression (86). 
 To be considered for analysis, researchers involved in Integrative Clinical Genomics of 





content (78).  Then, researchers collected DNA content to create an RNA transcriptome.  The 
transcriptome was sequenced for analytical use and was ultimately compared to the human 
reference genome (GRCh37/hg19) (78, 87).  Data from this study identify multiple gene, 
chromosome, and aneuploidy mutations in prostate cancers.  These cases had an average 
mutation rate of 4.4 mutations/Mb and an average number of relevant genetic mutations per 
case of 7.8, with the most common mutations occurring in androgen receptor (AR), TP53, and 
Phosphatase and Tensin Homolog (PTEN) genes.  Relevant to this project, Robinson et al.  also 
showed a substantial number of mutated PI3K pathway genes, vide infra.  (78). 
The role of androgen receptor signaling in prostate cancer can be traced back to the key 
role of androgen receptor signaling in prostatic development (47) and has been researched 
extensively (88-90).  Androgen deprivation therapy (ADT) utilizes agonists and antagonists of 
luteinizing hormone-releasing hormone and/or orchiectomy, a medical procedure removing one 
or both testicles, (91-93) and has been shown to decrease blood serum testosterone levels by as 
much as 98% (88).  Even after androgen deprivation therapy, prostate cancer cells can be seen 
inappropriately restoring androgen receptor synthesis.  These cells are considered castration-
resistant prostate cancer (CRPC) (78, 93).  Previous research regarding the role of TP53, a tumor 
suppressor gene, in androgen deprivation therapy resistance suggests malfunction of TP53 
results in the transition of epithelial-like, androgen receptor-dependent cancer cells to androgen 
receptor-independent, basal-like cells.  The ability of a cell to alter the phenotypic expression of 
its lineage has been termed lineage plasticity (94).  PTEN is a tumor suppressor gene involved in 





genes and the association of aberrations of these genes with nmCRPC and mCRPC cases of 
prostate cancer, it is clear that further understanding of these genes and pathways is crucial to 
advancement in the understanding and treatment of prostate cancer. 
 In vitro models of prostate cancer must be considered to promote clinical applicability of 
in vitro research findings; it is imperative to use a model mimicking the target clinical pathology 
of research outcomes.  To mimic clinical pathology as closely as possible, it is prudent to use in 
vitro models of prostate cancer in prostate cancer research.  However, this becomes challenging 
when one considers the various clinical presentations of the disease, vide supra (96). 
According to Risbridger et al., “patient derived preclinical models”, or samples of prostate 
cancer tissue sourced from human cases, can include xenografts, explants, and organoids.  To 
elaborate, a patient derived-explant (PDE) is a sliced cancerous tissue that can be prepared with 
mesenchyme to create a patient-derived xenograft (PDX) or suspended in a cell solution to create 
patient-derived organoid (PDO) (96).  Mesenchyme is an epithelium-derived tissue responsible 
for replenishment of the extracellular matrix, the cellular framework from which the body is built 
(97).  It is important to note that PDX, while considered the “gold standard” preclinical testing 
model, are particularly time and labor intensive for prostate cancer tissues (96).  So much so, in 
fact, that only approximately one percent of PDX models of human cancer for preclinical studies 
held in the Jackson Laboratory for Genomic Medicine PDX catalog are of prostate cancer (96, 98).  
The most conclusive collection of patient-derived prostate cancer cell line models is held by the 
Living Tumor Laboratory, totaling approximately 45 unique samples as of 2018 (96, 99).  





discussion will be on cell line models because they are relatively inexpensive and convenient to 
study when compared to PDX, mice, and/or human clinical research models. 
In the past, localized prostate cancer was routinely harvested during radical 
prostatectomy procedures.  With freezing and fixing techniques, previous research on these 
samples provided genomic data of the cells at time of harvest (96) .  However, research 
conducted on frozen or fixed cells gives only a static snapshot of the cell at time of harvest, and 
prostate cancer is known to progress and metastasize, often leading to fatality.  Additionally, an 
observable decline in progressive, localized samples has been seen due to early screening and 
effective treatment programs that mitigate disease progression.  Metastatic samples, on the 
other hand, have been historically harvested primarily from bone tissue.  Presently, modern 
tissue harvest practices have provided a variety of prostate cancer cell lines, each with unique 
genetic and phenotypic properties (96). 
AMP-Activated Protein Kinase 
AMP-activated protein kinase (AMPK) is an enzyme found in nearly every eukaryote and 
it is responsible for regulation of cell metabolism in response to stress.  AMPK allows cells to 
maintain a high and relatively constant concentration of ATP by sensing the ratio of ADP to ATP.  
Consequently, cells can increase catabolic and decrease anabolic pathways in response to ATP 
requirements (100).  Altering metabolic pathways allows the cell to conserve ATP during various 
conditions including low energy store, diabetes, cancer, and inflammation (101-103).  Because of 





 To understand the complex function and regulation of AMPK, one must have a basic 
understanding of enzyme’s structure.  AMPK is a heterotrimeric complex with one each of alpha, 
beta, and gamma subunits.  In mammals, there are two alpha, two beta, and three gamma 
isoforms which combine to form 12 unique AMPK isozyme complexes (100, 104, 105).  Isozyme 
expression is species and tissue dependent.  To elaborate, each isoform of AMPK is expressed in 
different concentrations depending on the species and tissue type of the cell expressing the 
isoform (100).  Positions of various subunit domains are determined by ligand binding, but a core 
of the enzyme is always formed by the gamma subunit, the alpha C-terminal domain (CTD), and 
the β- C-terminal domain.  The β-C-terminal domain is located between the alpha and beta 
subunit (105). 
The alpha subunit of AMPK is considered the catalytic component because it contains a 
serine/threonine kinase domain, an autoinhibitory domain (AID), and a serine/threonine rich 
area harboring phosphorylation sites known as the “ST loop”, and all of these components are 
involved in enzyme activity (104-106).  Humans express alpha-1 and alpha-2, which are encoded 
by the PRKAA1 and PRKAA2 genes, respectively (104).  There is a key regulatory threonine residue 
(T172) located in the kinase domain.  T172 phosphorylation by upstream kinases results in 
activation of AMPK (104-106).  The α-C-terminal domain interacts with the beta subunit and is 
the location of the ST loop.  The ST loop is where phosphorylation sites for upstream indicators 
of cellular energy status are located (104). 
The beta subunit functions both as a scaffolding protein between and as a regulatory unit 





the α-CTD, and a β-linker loop, the latter of which connects the β-CTD with the CBM (105).  The 
beta subunit contains a region known as the carbohydrate binding module (CBM) or glycogen 
binding domain (GBD) (100, 105, 107).  Humans express beta-1 and beta-2, encoded by the genes 
PRKAB1 and PRKAB2, respectively (104). 
  The gamma subunit is responsible for nucleotide-dependent regulation of AMPK.  Each 
gamma subunit isoform has an isoform specific N-terminus and an adenine nucleotide-binding 
domain (104-106).  Humans express γ1, γ2 and γ3, encoded by PRKAG1, PRKAG2, and PRKAG3 
genes, respectively (104).  The adenine nucleotide binding domain contains binding sites for 
adenine nucleotides AMP, ADP, and ATP.  These sites are known to be four motifs in the gamma 
subunit known as cystathionine-β-synthase (CBS) repeats.  The four repeats are named according 
to which ribose ring of adenine nucleotides AMP, ADP, and ATP the repeat binds to.  AMP, ADP, 
and ATP are thought to competitively bind to cystathionine-β-synthase repeats 1 and 3, 
suggesting this repeat may serve a potential target for AMPK activation  (104-106, 108, 109). 
  Activation of AMPK is primarily achieved via phosphorylation of threonine 172 (T172), 
which is within the kinase domain of the alpha subunit, and/or by binding of AMP and/or ADP to 
the gamma subunit (101, 104, 105, 108, 109).  The binding of AMP and/or ADP to the gamma 
subunit directly and allosterically activates AMPK and structurally prevents dephosphorylation of 
T172, which then increases AMPK activity by more than 200% (100, 110).  Two upstream enzymes 
responsible for T172 phosphorylation of AMPK are liver kinase B1 (LKB1; also known as STK11) 





Two additional methods to activate AMPK include binding of AMP analogs and endocrine 
influence.  AICAR, or 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranosyl-5-
monophosphate, is a natural by-product of de novo purine synthesis in humans.  In certain human 
pathologies, the enzyme adenylosuccinate lyase (ASL) converts the molecule succinyl-AICAR 
(SAICAR) to AICAR.  As AICAR accumulates, negative feedback occurs by AICAR on 
adenylosuccinate lyase (117).  Additionally, certain hormones, including ghrelin from fasting 
individuals and adiponectin from fat tissue of lean individuals, are thought to activate AMPK (108, 
109, 118). 
Inhibition of AMPK can occur through presence of ATP, which binds cystathionine-β-
synthase repeat 3 and prevents an alpha subunit region called the alpha-hook or alpha regulatory 
subunit interacting motif (α-RIM2) from interacting with cystathionine-β-synthase repeat 3.  
Interaction between the α-hook and cystathionine-β-synthase repeat 3 stabilizes the active 
conformation of AMPK when ATP is not bound to cystathionine-β-synthase repeat 3 (100, 109).  
Although there are a variety of AMPK-activating compounds, only Compound C has been 
identified as a cell-permeable inhibitor of AMPK (ref).  However, Compound C is relatively 
nonspecific and is believed to affect various kinases.  Therefore, Compound C is not ideal for 
studies of AMPK activity (119).  One hormone thought to inhibit AMPK is leptin, which is secreted 
from adipocytes of obese individuals (108, 109, 120). 
Downstream targets of AMPK have a net downstream effect of activation of catabolic 
pathways and inhibition of anabolic pathways to conserve intracellular ATP concentrations (100, 





thought to be important in recognition of substrates by AMPK (109).  In rats, the first substrate 
identified for AMPK was acetyl-CoA carboxylase-1 (ACC1) (123).  In humans, AMPK 
phosphorylates ACC1 at S80 and ACC2 at S222 (36).  Other possible targets of AMPK include, but 
are not limited to, 2-hydroxy-3-methylglutaryl-coA (HMG-CoA) reductase, glycogen synthase and 
tuberous sclerosis gene products TSC1 and TSC2 (108, 121, 122, 124).  TSC1 and TSC2 regulate 
the GTPase Rheb, which directly interacts with and inhibits mTORC1 (124).  This relationship 
between AMPK and mTORC1, led to the exploration of the relationship between AMPK, the 
mTOR pathway, and inhibition of cancer cell growth. 
The mTOR Pathway 
 Another highly conserved serine/threonine kinase involved in cancer metabolism includes 
the mammalian target of rapamycin (mTOR), which is a 289 kDa serine/threonine kinase that 
forms the complexes mTORC1 and mTORC2 (125, 126).  The mTOR pathway, also known as the 
phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of rapamycin 
(PI3K/AKT/mTOR) signaling cascade, involves the role of growth factors, nutrient availability, and 
energy availability in cell viability, proliferation, and motility.  Inhibition of the mTOR pathway 
was first discovered using the compound rapamycin and is thought to play a role in prevention 
of tumor progression and metastasis (125-127). 
 Phosphatidylinositol 3-kinase (PI3K) represents a group of kinases normally involved in 
translating extracellular growth signals of nutrient availability so that the cell may begin 
macromolecule synthesis and initiate cell cycle progression.  However, PI3K enzymes have been 





systemic regulation (128).  There are three classes of PI3K enzymes, with all forms being 
composed of a PI3K signature motif containing a C2 domain, a helical domain, and a catalytic 
domain.  PI3K classification is based on additional protein domains and how they interact with 
regulatory subunits (129).  Class I PI3K enzymes can be divided into two categories, with class IA 
associated with receptor tyrosine kinases (RTK) and class IB associated with G-protein coupled 
receptors.  RTKs have extracellular domains believed to bind growth factors including epidermal 
growth factors, platelet-derived growth factors, and insulin.  The class IA catalytic subunit isoform 
p110α is essential for proliferation during embryogenesis and oncogenic transformation.  
Interestingly, PIK3CA, the gene encoding for p110α, is mutated and/or amplified in many tumors.  
The regulatory subunit of class IA enzymes, p85α, is encoded by the gene PIK2R1 and contains a 
domain, Src homology 2, which allows binding of phosphorylated tyrosines to proteins.  This 
suggests p85 regulatory domains allow RTKs to associate with the p110 catalytic domain.  Many 
tumor-specific mutations in PIK3R1 and PIK3CA prevent or decrease p110α inhibition by p85α, 
thus increasing PI3K signaling.  When p85-p110 heterodimers bind to insulin receptor-insulin-
receptor substrate protein complexes, an important second messenger known as 
phosphatidylinositol 3,4,5-trisphosphate (PIP3) is produced at the plasma membrane (128). 
 The production of PIP3, which recruits proteins to the plasma membrane via a target motif 
called the pleckstrin-homology (PH) domain, results in PIP3 recruiting members of the AKT family 
of serine-threonine kinases to the plasma membrane (ref).  Binding of PIP3 to AKT PH domains 
allows AKT enzymes to meet another PH domain–containing protein kinase, 3-phosphoinositide–





enzyme (128) When localized to membranes, AKT can also be activated via phosphorylation at 
S473 by mTORC2.  AKT enzymes are mutated in many cancer cells and involved in many cell 
processes leading to tumorigenesis (130) Activated AKT is known to inhibit apoptosis and 
encourage proliferation.  One mechanism of AKT influence includes AKT phosphorylating and 
inactivating TSC1/2, which causes Ras homologue enriched in brain (RHEB) bound to GTP to 
accumulate and, subsequently, stimulate mTORC1 activity (131).   
The complexes mTORC1 and mTORC2 contain raptor and rictor, respectively (132).  The 
isoform mTORC1 is activated by growth factors and adequate supply of amino acids, but the exact 
mechanism of activation of mTORC1 remains unclear.  The isoform mTORC1 stimulates protein 
synthesis through phosphorylation and inactivation of the initiation factor known as 4E binding 
protein 1 (4E-BP1), a repressor of mRNA translation (131).  Although 4E-BP1 is phosphorylated at 
seven sites, phosphorylation of T37 is considered a priming event in the mTOR pathway (131, 
133-135).  There is evidence suggesting mutations in eukaryotic translation initiation factor 2B 
(eIF2B), which complexes with 4E-BP1 for activation of both enzymes, is implicated in 
development of mitochondrial malfunction and cancer development (132, 133, 135, 136). 
Inhibition of mTOR typically occurs through a lack of nutrients and growth factors and 
induces protein breakdown by autophagy, vide infra (132).  The mTORC1 enzyme can be inhibited 
by lack of growth factors and/or nutrients, and/or through various compounds, including 
rapamycin, the compound after which the enzyme is named, and its analogues everolimus (125, 
126, 131, 132, 137, 138).  AMPK has also been shown to inhbit mTORC1 via phosphorylation of 





have been shown to inhibit tumor cell proliferation, some through inhibition of mTOR (140, 141) 
Isoprenoids, also known as terpenes or terpenoids, are composed of multiple five carbon 
isoprene units.  Isoprenoids are secondary products of mevalonate metabolism and lead to 
cancer cell death (140, 141).  Some pure isoprenoids, including perillyl alcohol and geraniol, 
suppress HMG-CoA reductase by decreasing efficiency of HMG-CoA reductase transcript 
translation (140-142). 
In summary, energetic stress within a cell results in binding of ADP and, preferentially, 
AMP to the gamma subunit of AMPK, which activated the enzyme.  Additionally, upstream 
kinases such as LKB1 and CaM kinase kinase phosphorylate AMPK at T172, which results in more 
than a two-fold increase in activation of the enzyme.  AMPK then phosphorylates TSC2, which 
blocks Rheb, an enzyme involved in mTOR activation.  AMPK can also directly inhibit 
phosphorylation and activation of mTORC1.  AMPK also inhibits mTORC1.  The enzyme mTORC1 
is responsible for phosphorylation and activation of S6K, an enzyme responsible for 
phosphorylation and activation of ribosomal subunits.  The enzyme mTORC1 is also responsible 
for inhibition of 4E-BP1, an mRNA translation factor involved in tumor suppression.  In contrast, 
growth factors are recognized by the enzyme PI3K, which then activates AKT.  AKT activates 
mTOR.  These metabolic pathways have been implicated in a variety of metabolic diseases and 
cancers and have been extensively studied in cancer research, but little research exists regarding 





Mitophagy and Autophagy 
Autophagy is the degradation of cytosolic organelles and protein for use in recycling of 
cellular products during nutrient deprivation.  Autophagy occurs under times of extreme 
metabolic stress, but is repressed by mTOR during times of cell growth and proliferation.  In 
mammals, it is proposed that autophagy is initiated by activation of the enzymes Bcl2/E1B 19 
kDa-interacting protein 3-like protein (BNIP3), Nix (also known as BNIP3L), unc-51 like autophagy 
activating kinase 1 (ULK1), and autophagy gene (Atg) proteins (100, 101, 108, 109, 143-149).  
When autophagosomal machinery becomes overwhelmed, the cell is believed to initiated 
programmed cell death via apoptosis (150, 151). 
AMPK and mTOR have been shown to impose opposing regulation on autophagic 
machinery through the ULK1 and Atg pathways (101, 109, 139, 148, 149, 152-155).  In short, the 
Atg family of protein complexes is responsible for initiation of autophagy.  Atg6, which contains 
PI3K, and Atg1, which is suppressed by mTOR, are essential for the formation of pre-
autophagosomal structures.  These structures are then ubiquitinated within the cell, which is 
followed by maturation of pre-autophagosomal structures to autophagic membranes and 
machinery.  Atg7 and Atg8 are heavily involved in the latter process (148). 
In mammals, AMPK promotes and mTOR inhibits autophagy by direct phosphorylation of 
ULK1 (139, 152, 153, 155).  One experiment showed evidence that AMPK directly phosphorylates 
ULK1 at S317 and S777.  Controls in these experiments included AMPK inhibition by ATP rich 





human cells, which may have ULK1 phosphorylation sites in different locations.  Further research 
is needed to assess AMPK phosphorylation of ULK1 in human cells. 
Mitophagy is the process wherein defective or unnecessary mitochondria are degraded 
by autophagic machinery (156, 157).  The mitochondria are cell organelles responsible for 
production of ATP and essential for cell metabolism, viability, and proliferation (158, 159).  In 
addition, mitochondria are the primary source of endogenous reactive oxygen species (ROS) 
production and the release of these ROS molecules may be correlated with cancer development 
(160, 161).  In normal cells, the re-construction of mitochondria may occur as a response to 
mitochondrial malfunction, which may be a normal and necessary response to everyday events 
as simple as exercise induced stress (162, 163).  This reconstruction, termed mitochondrial 
biogenesis, is paired with the continuous breakdown of inefficient mitochondria, mitophagy (162, 
164, 165). 
Mitochondrial malfunction has been identified in many human pathologies, including 
metabolic and age-related diseases (136, 160, 161, 166, 167).  During mitophagy, the 
mitochondrion is surrounded by the autophagosome so that it may be transferred to the 
lysosome for hydrolytic degradation.  If the volume of damaged mitochondria surpasses that 
manageable by autophagic machinery, cell death initiates (41, 156, 157, 164, 165, 168).  
However, some cancer cells have been able to bypass this natural response to overwhelming 






Interestingly, little development has occurred regarding quantitative measurement of 
mitophagy in vivo (144-146).  Qualitative analysis of mitophagy can occur via transmission 
electron microscopy, wherein one can expect to observe the development of double-membrane 
autophagosomes.  Furthermore, pieces of or entire cell organelles, including mitochondria, can 
be found in autophagosomal machinery (144-146, 169).  Quantitative assessment of mitophagy 
in cells in vitro includes fluorescence microscopy assays, immunoblotting for mitophagy proteins, 
and mitochondrial mass assays, among other means (144-146). 
AIMS AND GOALS 
Previous Research 
Peffley et al.  published a study regarding isoprenoids.  Researched treated PC3 cells with 
400 uM of perillyl alcohol or geraniol for 16 hours before western blot analysis, including analysis 
of 4E-BP1 phosphorylation, a final substate of the mTOR pahtway.  Data from this experiment 
suggest the isoprenoid perillyl alcohol decreases proliferation of PC3 cell lines in part via 
inhibition of the PI3K/AKT/mTOR pathway (140). 
Rae et al.  published a study which observed the role of AICAR in activation of AMPK in 
PC3 and LNCaP cell lines.  These researchers treated PC3 and LNCaP cells with .5, 1, and 3 mM 
solutions of AICAR suspended in media before western blot analysis of phosphorylation of acetyl-
coA.  They also used a 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) 
toxicity assay to assess viability of treated cells.  Results show a concentration-dependent 
increase in phosphorylated ACC and decrease in cell viability (170), though there is no mention 





The above evidence shows that AMPK activation via phosphorylation at T172 may occur 
with the perillyl alcohol, geraniol, and/or AICAR in the prostate cancer cell line PC3, this cell line 
was the first investigated. 
Hypothesis 
 The hypothesis of this project is that activation of AMPK leads to increased mTOR-
dependent mitophagy and subsequent autophagy in prostate cancer cells. 
Specific Aim 1 
 The first aim of this project is to determine whether the treatment of prostate cancer cell 
lines (PC-3) with perillyl alcohol, geraniol, and/or AICAR mediate increased activation of AMPK.  
The goal of this aim is to determine compounds for use in future experiments that increase 
activation of AMPK. 
The hypothesis of this aim is that PC-3 cells treated with perillyl alcohol, geraniol, AICAR 
will exhibit a dosage-dependent increase in T172-phosphylated AMPK and S80-phosphorylated 
ACC1 when controlled against these same enzymes not specifically phosphorylated at these sites.  
Furthermore, a dosage-dependent decrease in T37-phosphorylated 4E-BP1 is expected because 
activated AMPK has been shown to inhibit mTORC1 and mTORC1 phosphorylates and inactivates 
4E-BP1.  Rapamycin, a direct mTOR inhibitor, will be used as a control treatment for inhibition of 
the PI3K/AKT/mTOR pathway. 
In this aim, PC-3 cells will be directly treated with various concentrations of perillyl 





will be dictated by previous research (140, 170).  Varying concentrations of these compounds will 
be used to identify optimal activation conditions for AMPK.  Activation of AMPK will be evaluated 
via western blot analysis of the enzymes AMPK, ACC, and 4E-BP1 and their phosphorylated 
counterparts p-AMPK (T172), p-ACC (S80), and p-4E-BP1 (T37).  With both experiments, expected 
results include an increase in p-AMPK (T172) and p-ACC (S80) and a decrease in p-4E-BP1 (T37) 
when compared to their non-phosphorylated forms.  These experiments will establish the role of 
perillyl alcohol, geraniol, and/or AICAR in activation of AMPK and the relationship that activation 
of AMPK has to the mTOR pathway. 
Specific Aim 2 
 The second aim of this project is to determine whether pharmaceutically induced 
activation of AMPK leads mitophagy in prostate cancer cell lines.  The goal of this aim is to lay a 
framework for the understanding of potential pathways and mechanisms through which AMPK 
influences mitophagy through autophagy.  Previous research, vide supra, suggests mitochondrial 
malfunction may enlist autophagic machinery to dispose of the mitochondria via mitophagy.  The 
autophagic machinery may be met with an overwhelming quantity of damaged mitochondria, in 
which cause the cell self-induces autophagy and subsequent apoptosis.  AMPK and mTOR have 
been shown to impose opposing regulation on mitophagy via regulation of autophagic machinery 
by the NIX, ULK1, and autophagic gene (Atg) pathways. 
The hypothesis of this aim is that activation of AMPK will activate mitophagy in PC3 cells.  
In addition, activation of AMPK will inhibit mTORC1 influence on mitophagy pathways in PC3 





To test this hypothesis, PC-3 cells will be directly treated with optimal concentrations of 
perillyl alcohol, geraniol, and/or AICAR.  Timing and dosage of treatment with these compounds 
will be dictated by previous research and results of specific aim 1.  AMPK influence on mitophagy 
in PC3 cells will first be analyzed via transmission electron microscopy.  Expected results will 
include observed development of double-membraned autophagosomes and the envelopment of 
organelles, including mitochondria, by autophagosomes (144, 169).  After confirmation of 
mitophagy development via qualitative analysis, mitophagy will then be analyzed by fluorescence 
microscopy for mitochondria-autophagosome colocalization.  Mitotracker will be used for live-
cell imaging of mitochondria and GFP-LC3 will be used for identification of autophagosomal 
structures (171, 172).  Expected results include the movement of mitochondria and/or 
autophagosomal machinery into contact with each other.  Finally, mitophagy will be assessed via 
immunoblotting assay probing for proteins that are autophagosomal, involved in mitophagy, and 
regulated by AMPK and/or mTOR.  The enzymes that will be probed for include NIX, ULK1, and 
Atg proteins Atg1, Atg7, and Atg8.  However, research regarding the AMPK-dependent activation 
of these enzymes remains to be explored.  These experiments will further elucidate the 
relationship between AMPK activation and mitophagy. 
Specific Aim 3 
 The third aim of this project is to determine whether pharmaceutically induced activation 
of AMPK in pc3 cells leads to autophagy.  The goal of this aim is to determine whether activation 





The hypothesis of this aim is that AMPK-activated mitophagy leads to subsequent 
autophagy in prostate cancer cells. 
To test this hypothesis, PC-3 cells will be directly treated with optimal concentrations of 
perillyl alcohol, geraniol, and/or AICAR.  Timing and dosage of treatment with these compounds 
will be dictated by previous research and results of specific aim 1.  Autophagy will first be 
confirmed via transmission electron microscopy analysis as described in specific aim 2.  Protein 
samples from treated cells will then be used to perform western blot analysis on baseline and 
autophagy-dependent changes in NIX, ULK1, and autophagic gene (Atg) proteins.  Expected 
results include an increase in active autophagic machinery in cells treated with AMPK activators.  
This aim should help to further clarify how AMPK activation inhibits prostate cancer progression 






Reagents and cell lines.  PC-3 cell lines (ATCC CRL-1435) acquired from American Type Culture 
Collection (ATCC, Manassas, VA) and stored in a vapor-phase liquid nitrogen freezer.  Perillyl 
alcohol (product ID #8578S), geraniol (product ID #163333), and AICAR (product ID #A9978) were 
sourced from Sigma-Aldrich (St.  Louis, MO).  Each compound was stored according to 
manufacturer instruction.   
Cell culture.  All work performed with live cells and reagents for cell culture occurred under a 
sterile, laminar flow hood.  The working hood was sterilized with ultraviolet light for 15 minutes 
followed by wiping with 70% ethanol from a spray bottle and a sterile tissue.  During the 15-
minute sterilization of hood with ultraviolet light, Roswell Park Memorial Institute Medium 
(RPMI-1640) medium with L-glutamine (Sigma-aldrich, St Louis, MO), fetal bovine serum (FBS), 
and a solution of combined antibiotic (Penicillin and Streptomycin solution, 100x, Mediatech Inc., 
a Corning subsidiary, Manassas, VA) and antimycotic (Amphotericin B, Thermo Fisher Scientific, 
Waltham, MA) were placed in 37°C bath.  The antibiotic and antimitotic solution contains 10,000 
units/mL of penicillin, 10,000 µg/mL of streptomycin, and 25 µg/mL of amphotericin B.  Complete 
media was created using 500 mL RPMI-1640, 50 mL FBS, and 5 mL antibiotic and antimycotic 
solution.  A 50 mL syringe was used to force the complete media through a 22-micron media 
filter.  Filtered complete media was distributed into 50 mL aliquots and stored the aliquots at 8oC 
for later use.  For resuscitation of cells from liquid nitrogen storage, 10 ml of complete medium 
was first added to a T75 flask.  Both the T75 flask and the 15 mL conical were placed in the 





culture cryotube was sterilized, opened under the hood, closed tightly, and warmed in a 37°C 
bath with gentle agitation for 2 minutes.  The T75 flasks were then removed from the incubator, 
sterilized with 70% ethanol, and placed in the hood.  Cells suspended in cryopreservation solution 
were transferred to the 15 mL conical tube containing 9 mL complete media.  The student then 
centrifuged the conical containing media, cryopreservation solution, and cells at 130 x g for 10 
minutes at 25°C.  The student used a 1000 uL pipette with a sterile tip to remove supernatant 
before resuspending the cells in 1 mL of complete growth medium.  Finally, 1 ml of cell suspension 
was added to the 10 mL of complete medium in the T75 flask.  Cell cultures were examined after 
24 hours and an exchange of media occurred every 48 hours until the cells reached approximately 
80-90% confluence within the t75 vessel. 
Cell treatment assays.  Each cell culture passage was grown until approximately 80-90% 
confluency.  Cells appearing in exponential growth were seeded at approximately 700,000 cells 
per 60 mm polystyrene tissue culture plate for use in experiments.  Triplicates for each treatment 
were plated.  Once seeded, cells grew in the incubator for 24-48 hours or until 80% confluency 
before media exchange for treatment.  Controls for cell treatment assays consisted of cells 
incubated in only complete media.  Control treatments were conducted in triplicate and 
simultaneously with cell treatments consisting of perillyl alcohol, geraniol, and AICAR, 
treatments.  Cell treatment were also performed in triplicate.   Isoprenoids, including perillyl 
alcohol and geraniol, were used to treat cells for 24 hours according to the protocol outlined in 
previous research, vide infra (140).  Pipettes with sterile tips were used to suspend perillyl alcohol 
(PA) or geraniol (G) in complete media.  Cells were treated with 400 uM of PA and/or G for 





methods set forth in previous research, vide infra (170).  Twelve to fifteen culture plates were 
seeded for each cell treatment assay: 3 replicates each of negative control, vehicle control (cell 
culture-grade DMSO, if used), .5 mM, 1 mM, and 3 mM of AICAR.  Cells were treated with AICAR 
for 24h. 
Cell lysis, protein harvest, and bicinchoninic acid (BCA) protein assay.  The remainder of the 
protocols described in these methods were conducted outside of the sterile hood on the bench 
top.  For cell lysis, control and treatment media was removed from experimental plates using 
pipettes and sterile tips.  The plates were immediately placed directly on ice in an ice bucket 
and/or pan and covered with their respective lids.   Three mL of ice-cold PBS was used to gently 
wash each plate.  Then 200 µl of RIPA Lysis Buffer with Inhibitors (Source, city, state) was added 
to each flask, swirled to distribute buffer, and the plate incuated on ice for 15 minutes.  A plastic 
sterile cell scraper was used to remove adherent cells in lysis solution A pipette and sterile tips 
were used to transfer the cell lysate to a 1.5 mL Eppendorf tubes.  The tubes were then 
centrifuged at 13000 x g for 5 minutes at 4°C.  The cell lysate supernatant, referred to as the 
protein concentrate from this point forward, was removed from each 1.5 mL Eppendorf tube and 
transferred to a new, sterile tube.  Protein concentration density of each sample was determined 
using a Pierce™ bicinchoninic acid (BCA) protein assay kit (Thermo-Fisher Scientific), per 
manufacturer instructions.  Protein concentrates were aliquoted into Eppendorf vessels based 
on protein concentration prior to storage at -20°C. 
Western blot analysis.  Protein concentrates used for western blot analysis were removed from 





concentration of each treatment group, protein concentrate was aliquoted such that each gel 
well would have a constant mass of proteins.  Protein concentrate was combined with 4x laemlli 
buffer and DI water before being heated to 85°C for 5 minutes.  Each sample was loaded into a 
4-20% Mini-PROTEAN TGX Gels (Bio-Rad Labratories, Inc., Hercules, Ca).  Negative and positive 
AMPK control lysates from C2C12 cells (product ID #9158, Cell Signaling Technology, Danvers, 
MA) were used in addition to lysates from control treatments of PC3 cells.  The western blot 
apparatus was set to 100 volts until the samples passed through stacking gel portion of gel, then 
voltage was raised to 180 volts.  Polyvinylidene fluoride (PVDF) membranes were soaked 100% 
ethanol for 15 minutes before being stacked with the gel in transfer solution.  The stack was then 
placed in a Turboblot (Bio-Rad) cassette to run at a constant 25 volts for 14 minutes.  The PVDF 
membrane was then placed in blocking buffer solution (LI-COR Biosciences, Lincoln, NE) for 1 
hour at room temperature.  Afterwards, the membrane was washed 3 times with PBS-T for 10 
minutes with gentle agitation on the rocker.  All PVDF membranes were probed with mouse anti-
B-actin (1:5000 ratio, Cell Signaling) in blocking buffer solution.  Each “A” labeled PVDF 
membrane was stained with rabbit primary antibodies against 4E-BP1, AMPKa, and ACC (1:1000 
each, Cell Signaling) in blocking buffer solution.  Each “B” labeled membrane was stained with 
rabbit primary antibodies against p-4E-BP1, p-AMPKa, and p-ACC (1:1000, Cell Signaling) in 
blocking buffer solution.  Primary antibodies were stained overnight at 4°C.  Afterwards, 
membranes were again washed three times with PBST for 10 minutes with gentle agitation.  
Membranes were then incubated with anti-mouse (red) and anti-rabbit (green) secondary 





minutes at room temperature.  Lastly, cells were rinsed 3 more times with PBST and transferred 








Figure 1: Western blot comparison of the effects of isoprenoids perillyl alcohol and geraniol on 
site-specific phosphorylation of 4E-BP1, AMPK, and ACC (A) and their phosphorylated 
counterparts PC3 cells (B). 
This experiment was conducted to confirm previous data suggesting the isoprenoids 
perillyl alcohol and geraniol decrease proliferation of PC3 cell lines in part via inhibition of the 
PI3K/AKT/mTOR pathway (140).  The hypothesis of this experiment is that PC3 cells treated with 
400 uM perillyl alcohol or geranial solutions for 24h would exhibit an increase in T172- 
phosphorylated AMPK and S80-phosphorylated ACC1 and a decrease in T37-phosphorylated 4E-
BP1 when controlled against these same enzymes not specifically phosphorylated at these sites. 
Although largely inconclusive, results show increased expression of 4E-BP1, a protein in 





investigation considering the hypothesis in that activation of AMPK should inhibit mTOR and thus 
decrease expression of T37-phosphorylated 4E-BP1.  Additionally, there seems to be some 








Figure 2: Western blot comparison of the effects of AICAR on site-specific phosphorylation of 4E-
BP1, AMPK, and ACC (A) and their phosphorylated counterparts PC3 cells (B). 
This experiment was conducted to confirm previous data suggesting the AMP-analogue 
AICAR activates AMPK in PC3 cells.  The hypothesis of this experiment is that PC3 cells treated 
with .5, 1, and 3 mM AICAR solutions for 24h would exhibit a dose-dependent increase in T172- 
phosphylated AMPK and S80-phosphorylated ACC1 and  decrease in T37-phosphorylated 4E-BP1  
when controlled against these same enzymes not specifically phosphorylated at these sites.   
 Although difficult to see, results show expression of T-80 phosphorylated ACC1 in PC3 






Figure 3: Western blot comparison of the effects of AICAR on site-specific phosphorylation of 4E-
BP1, AMPK, and ACC (A) and their phosphorylated counterparts PC3 cells (B). 
This experiment was conducted to confirm previous data suggesting the AMP-analogue 
AICAR activates AMPK in PC3 cells.  The hypothesis of this experiment is that PC3 cells treated 
with .5, 1, and 3 mM AICAR solutions for 24h would exhibit a dose-dependent increase in T172- 
phosphylated AMPK and S80-phosphorylated ACC1 and  decrease in T37-phosphorylated 4E-BP1  
when controlled against these same enzymes not specifically phosphorylated at these sites. 
Results of this experiment were inconclusive.   The double band appearance of the 






 As outlined in the introduction of this manuscript, research regarding the dualistic roles 
AMPK and mTOR impose on mitophagy and autophagy in in vitro models of prostate cancer is 
complex.  Although AMPK and mTOR are well established regulators of cell metabolism and 
growth, research regarding the dualistic role between the two enzymes on mitophagy and 
autophagy remains largely unexplored.  The following discussion will explore implications of 
results, scrutinize the theory and technique of this project, and investigate future directions of 
research. 
 Results from initial experiments could not be analyzed because there were no apparent 
results from protein concentrates of PC3 cell lines after perillyl alcohol, geraniol, and/or AICAR 
treatment.  However, control cell lysates seemed to exhibit an increase in ACC1 phosphorylation 
in serum starved C2C12 AMPK control cell lysates.  This shows that AMPK activation via serum 
starvation leads to increased phosphorylation of ACC1, but says nothing about the compounds 
used in this experiment.  An important note to be made regarding AMPK control lysates is that 
these lysates from C2C12 cells were used in comparison to lysates from control treatments of 
PC3 cells.  This was done in an attempt to ensure functionality of primary and secondary 
antibodies.  However, C2C12 are derived from mouse muscle cell lines, and therefore these 
AMPK control cell lysates should not bind to anti-human AMPKα1 (ATCC CRL-1772).  Results using 
anti-human AMPK alpha 1 antibodies against these cell lysates cannot be reliably assessed.  
Additionally, positive AMPK cell lysate controls exhibited an increase in T37-phosphorylated 4E-





autophagy through the mTOR pathway in mouse muscle cells.  One interesting take from initial 
experiments was the apparent double bands seen in beta actin proteins.  Though results from 
this experiment were inconclusive, a protease and phosphatase inhibitor cocktail will added to 
future cell lysate solutions. 
From a foundational level, it is important to have a solid understanding of research theory 
and technique.  Though some concepts, including western blot analysis, have been used for 
decades, the technique and application of experimental analysis is continuously evolving.   
Though cell culture was conducted according to supplier recommendations and under 
presumably sterile conditions, repeated infection of cell culture by what appeared to be a fungal 
source remained a significant barrier to productive research during this project.  Initially, PC3 
cells were incubated with 1% antibiotic solution immediately after resuscitation of cell culture 
directly from the distributor.  The antibiotic solution contained the antibiotics penicillin and 
streptomycin, both shown to prevent bacterial contamination of cell cultures due to their 
effective combined action against gram-positive and gram-negative bacteria, respectively (173, 
174).  However, treatment of cell cultures with antibiotics has been implicated in a variety of 
undesired outcomes, including genomic and morphological changes (175).   
Cells were treated with antibiotic solution in hopes of mitigating bacterial contamination 
and based on previous research with PC3 cells (140).  However, PC3 cell cultures showed 
repeated evidence of fungal contamination across multiple passages.  Amphotericin B has been 
shown to prevent fungal contamination of cultures due to the compound’s inhibition of multi-





undesired effects on cells in vitro, including alteration of proteomes (176-179).  In the future, it 
will be imperative to investigate best practice for mitigation of bacterial and/or fungal 
contamination and adhere best practice as strictly as possible (175, 179-181). 
A major improvement in cell treatment assays would include further exploration into 
time- and dosage-dependent outcomes of prostate cancer cell treatment with perillyl alcohol, 
geraniol, and/or AICAR to activate AMPK.  Once the optimal time and dosage of treatment to 
activate AMPK is determined, optimal concentrations can be used for manipulation of AMPK-
regulated pathways.  As mentioned in aim 1, implementation of this investigation can be as 
simple as preliminary research comparing various dosages and treatment times of compounds in 
benign prostatic and prostatic cancer cell lines. 
Western blot analysis is a three-part protocol beginning with cell lysis, protein harvest, 
and protein density assays.  During this time, a variety of reagents are used to break open the 
cell, store un-altered protein, and determine the concentrations of these protein samples.  The 
unexpected double banded appearance of the housekeeping gene beta actin suggests an issue 
may have occurred during cell lysis or protein harvest.  Because of this, a protease and 
phosphatase inhibitor should be added to future samples. 
The second part of western blot analysis requires that these proteins are electrically 
pulled through a sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel and 
then transferred to a polyvinylidene fluoride (PVDF) membrane.  In order to successfully pull 
these proteins through the gel and accurately analyze the results, it is important that proper care 





experiments, varying concentrations and volumes of protein concentrate samples were used in 
analysis.  In future experiments, it is imperative to establish a standard volume and concentration 
of protein lysate solution.  Additionally, although pre-cast gels were used in preliminary 
experiments, it may be appropriate to hand-cast gels with the specific protein to be probed for 
in mind (182). 
The final component of western blot analysis includes the production of densitometric 
data and computational analysis of that data.  Densitometric data is produced digitally by 
comparing the brightness of proteins on a western blot images first to the background 
fluorescence, then to proteins of other samples (182).  Unfortunately, the low reliability and 
accuracy of western blot results from preliminary experiments prevented the generation and 
statistical analysis of data.  However, it is imperative that an appropriate and reliable statistical 
analysis comparing treatments and outcomes be established. 
Future Research 
Because evidence shows that AMPK activation via phosphorylation at T172 may occur 
with the perillyl alcohol, geraniol, and/or AICAR in the prostate cancer cell line PC3, this cell line 
was the first investigated.  However, future research should include in vitro studies of AMPK in 
human benign prostatic and prostate cancer cell lines. For prostate cancer cell line research, it 
may be helpful to classify prostate cancer cell lines by androgen-dependent or androgen-
independen because these differing physiologies significantly alter prostate cancer cell line 





cell line LNCaP and androgen-independent would include the cell lines PC3 and DU-145 (185-
188). 
One experiment showed evidence that AMPK directly phosphorylates ULK1 at S317 and 
S777 in mouse cells.  Controls in these experiments included AMPK inhibition by ATP rich 
environments and compound C (139).  However, neither this study nor a subsequent literature 
search produce identification of the serine or threonine residue phosphorylated by AMPK on 
ULK1 in human prostate cancer cells.  It is important to consider that AMPK may act on 
serine/threonine residues in a species- and tissue- specific manner (104, 105, 124, 139, 152, 153, 
170).  For this reason, future research should include studies of ULK1 phosphorylation by AMPK 
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Figure 1: Western blot comparison of the effects of isoprenoids perillyl alcohol and geraniol on 
site-specific phosphorylation of 4E-BP1, AMPK, and ACC (A) and their phosphorylated 
counterparts PC3 cells (B).  Cells were treated with 400 uM of PA and G for approximately 24h.  
Rabbit anti-human primary antibodies were used to probe PVDF membranes.  The membrane 
labeled A was probed, using rabbit anti-human primary antibodies, for 4E-BP1, AMPKa, and ACC 
(A).  The membrane labeled B was probed for phosphorylated 4E-BP1, AMPKa, and ACC, 
phosphorylated at T37, T172, and S80, respectively (B).  Both membranes were also probed with 
mouse anti-antihuman B-actin, which serves as a housekeeping control in these experiments.  
Beta actin should be visualized at approximately 42 kDa (red).  AMPK should be visualized at 
approximately 63 kDa (green).  4E-BP1 has a molecular weight of 15 kDa (green).  ACC has a 






Figure 2: Western blot comparison of the effects of AICAR on site-specific phosphorylation of 4E-
BP1, AMPK, and ACC (A) and their phosphorylated counterparts PC3 cells (B).  Cells were treated 
with control, .5, 1, or 3 mM of AICAR for 24h.  Rabbit anti-human primary antibodies were used 
to probe PVDF membranes.  The membrane labeled A was probed, using rabbit anti-human 
primary antibodies, for 4E-BP1, AMPKa, and ACC (A).  The membrane labeled B was probed for 
phosphorylated 4E-BP1, AMPKa, and ACC, phosphorylated at T37, T172, and S80, respectively 
(B).  Both membranes were also probed with mouse anti-antihuman B-actin, which serves as a 
housekeeping control in these experiments.  Beta actin should be visualized at approximately 42 
kDa (red).  AMPK should be visualized at approximately 63 kDa (green).  4E-BP1 has a molecular 







Figure 3: Western blot comparison of the effects of AICAR on site-specific phosphorylation of 4E-
BP1, AMPK, and ACC (A) and their phosphorylated counterparts PC3 cells (B).  Cells were treated 
with control, .5, 1, or 3 mM of AICAR for 24h.  Rabbit anti-human primary antibodies were used 
to probe PVDF membranes.  The membrane labeled A was probed, using rabbit anti-human 
primary antibodies, for 4E-BP1, AMPKa, and ACC (A).  The membrane labeled B was probed for 
phosphorylated 4E-BP1, AMPKa, and ACC, phosphorylated at T37, T172, and S80, respectively 
(B).  Both membranes were also probed with mouse anti-antihuman B-actin, which serves as a 
housekeeping control in these experiments.  Beta actin should be visualized at approximately 42 
kDa (red).  AMPK should be visualized at approximately 63 kDa (green).  4E-BP1 has a molecular 
weight of 15 kDa (green).  ACC has a molecular weight of 265 kDa (green). 
